https://sputnikglobe.com/20211230/china-to-keep-working-with-russia-on-vaccines-including-mutual-recognition-ambassador-says-1091898940.html
China to Keep Working With Russia on Vaccines, Including Mutual Recognition, Ambassador Says
China to Keep Working With Russia on Vaccines, Including Mutual Recognition, Ambassador Says
Sputnik International
MOSCOW (Sputnik) - China will keep working with Russia on cooperation issues related to COVID-19 vaccines, including mutual recognition of medicines, Chinese Ambassador to Russia Zhang Hanhui said in an interview with Sputnik.
2021-12-30T00:09+0000
2021-12-30T00:09+0000
2021-12-30T00:09+0000
russia
china
ambassador
vaccine
pandemic
covid-19
https://cdn1.img.sputnikglobe.com/img/07e5/07/08/1083333351_0:160:3073:1888_1920x0_80_0_0_8f137779176dc6019a7992a000bebaff.jpg
"Vaccines are an important weapon required to finally defeat the COVID-19 pandemic. China is ready to liaise with other countries, including the Russian side, on cooperation issues related to vaccines against the novel coronavirus, including the mutual recognition of essential vaccines by the two countries, to effectively reduce the risk of cross-border epidemic transmission and promote a new order of healthy, safe and orderly movement of people,” Zhang said.The ambassador recalled that in November 2020, the third phase of clinical trials of a new recombinant vaccine against coronavirus (Ad5-nCoV) produced by CanSino Biologics was completed in Russia, on the basis of which the vaccine was conditionally allowed for sale in China and is now undergoing the application process for its registration in Russia.In addition, clinical trials of the third phase of a recombinant novel coronavirus vaccine with fusion protein (V-01) have begun in Russia. The Russian Direct Investment Fund has signed agreements with several Chinese manufacturers to produce in China 150 million doses of Russia's Sputnik V and Sputnik Light vaccines annually, Zhang said.
https://sputnikglobe.com/20211228/sputnik-v-developers-to-putin-trials-show-the-russian-vaccine-neutralises-omicron-strain-1091858897.html
russia
china
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
https://cdn1.img.sputnikglobe.com/img/07e5/07/08/1083333351_170:0:2901:2048_1920x0_80_0_0_b2b55f4f24f8df3e6070e018486147de.jpgSputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
china-russia cooperation on vaccines, covid-19 vaccines, russian covid vaccine, chinese vaccine against covid
china-russia cooperation on vaccines, covid-19 vaccines, russian covid vaccine, chinese vaccine against covid
China to Keep Working With Russia on Vaccines, Including Mutual Recognition, Ambassador Says
MOSCOW (Sputnik) - China will keep working with Russia on cooperation issues related to COVID-19 vaccines, including mutual recognition of medicines, Chinese Ambassador to Russia Zhang Hanhui said in an interview with Sputnik.
"Vaccines are an important weapon required to finally defeat the COVID-19 pandemic. China is ready to liaise with other countries, including the Russian side, on cooperation issues related to vaccines against the novel coronavirus, including the mutual recognition of essential vaccines by the two countries, to effectively reduce the risk of cross-border epidemic transmission and promote a new order of healthy, safe and orderly movement of people,” Zhang said.
"Sino-Russian cooperation related to vaccines against the novel coronavirus is close and effective," he said.
28 December 2021, 11:47 GMT
The ambassador recalled that in November 2020, the third phase of clinical trials of a new recombinant vaccine against coronavirus (Ad5-nCoV) produced by CanSino Biologics was completed in Russia, on the basis of which the vaccine was conditionally allowed for sale in China and is now undergoing the application process for its registration in Russia.
In addition, clinical trials of the third phase of a recombinant novel coronavirus vaccine with fusion protein (V-01) have begun in Russia. The Russian Direct Investment Fund has signed agreements with several Chinese manufacturers to produce in China 150 million doses of Russia's Sputnik V and Sputnik Light vaccines annually, Zhang said.